Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
Schrijvers D, Bos AM, Dyck J, de Vries EG, Wanders J, Roelvink M, Fumoleau P, Bortini S, Vermorken JB. Schrijvers D, et al. Among authors: roelvink m. Ann Oncol. 2002 Mar;13(3):385-91. doi: 10.1093/annonc/mdf061. Ann Oncol. 2002. PMID: 11996468 Free article. Clinical Trial.
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Among authors: roelvink m. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB. Bos AM, et al. Among authors: roelvink mw. Cancer Chemother Pharmacol. 2001 Nov;48(5):361-9. doi: 10.1007/s002800100350. Cancer Chemother Pharmacol. 2001. PMID: 11761453 Clinical Trial.
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P; European Organization for Research and Treatment of Cancer (EORTC). Coudert B, et al. Among authors: roelvink m. Eur J Cancer. 2001 Nov;37(17):2194-8. doi: 10.1016/s0959-8049(01)00286-6. Eur J Cancer. 2001. PMID: 11677106 Clinical Trial.
Aujeszky's disease in horses fulfils Koch's postulates.
Kimman TG, Binkhorst GJ, van den Ingh TS, Pol JM, Gielkens AL, Roelvink ME. Kimman TG, et al. Among authors: roelvink me. Vet Rec. 1991 Feb 2;128(5):103-6. doi: 10.1136/vr.128.5.103. Vet Rec. 1991. PMID: 1850887